|
|
|
|
|
|||||||
|
Session 34
Oral Abstract Session
Late Breakers II Thursday, 9:30 - 11:45 am 4B |
| Moderators |
Constance Benson, Univ. of Colorado Hlth. Sci. Ctr., Denver and David Ho,
Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY | ||
| 9:30 LB9. | Cardio- and Cerebrovascular Outcomes with Changing Process of Anti-HIV Therapy in 36,766 US Veterans S. A. Bozzette*1,2,4, C. Ake1,2, A. Carpenter3, U. Bommakanty1, V. Leung1, H. Tam1,2, R. Smith3, A. Schepps1, and T. Louis4 1VA, Med. Ctr., San Diego, CA; 2Univ. of California, San Diego; 3Data Explorations, San Diego, CA; 4RAND, Santa Monica, CA; and 5RAND, Arlington, VA
| ||
| 9:45 LB10. | Effect of Indinavir (IDV) Monotherapy on Endothelial Function in Men without HIV Infection M. P. Dubé*, S. Shankar, J. M. Vanderluitgaren, C. M. Leffler, A. D. Baron, and H. O. Steinberg Indiana Univ., Indianapolis
| ||
| 10:00 LB11. | Impaired Glucose Phosphorylation in Skeletal Muscle Causes Insulin Resistance in HIV-1 Infected Patients with Lipodystrophy G. M. N. Behrens, A.-R. Boerner, K. Weber, J. van den Hoff, J. Ockenga, G. Brabant, and R. E. Schmidt* Hannover Med. Sch., Germany
| ||
| 10:15 LB12. | Analysis of Gluconeogenesis Using Stable Isotopes in Patients with HIV B. C. Weis1, D. Margolis*1&2, M. E. Merritt1, S. C. Burgess1, and C. R. Malloy1&2 1Univ. of Texas Southwestern Med. Ctr., Dallas and 2Dallas Veterans Affairs Med. Ctr., TX
| ||
| 10:30 LB13. | Rosiglitazone in the Treatment of HAART Associated Lipodystrophy (HAL): A Randomized, Double-Blind, Placebo-Controlled Study J. Sutinen*, A. M. Hakkinen, J. Westerbacka, S. Vehkavaara, J. Halavaara, A. Jarvinen, M. Ristola, and H. Yki-Jarvinen Helsinki Univ. Hosp., Finland
| ||
| 10:45 LB14. | Recently Identified Adverse Events Secondary to NRTI Therapy in HIV-Infected Individuals: Cases from the FDA’s Adverse Event Reporting System (AERS) K. Marcus*, M. Truffa, D. Boxwell, and J. Toerner FDA, Rockville, MD
| ||
| 11:00 LB15. | A Randomized, Controlled Trial of Pegylated Interferon R. Chung*, J. Andersen, B. Alston, M. Vallee, G. Robbins, T. Nevin, D. Colquhoun, K. Sherman, M. Peters, G. Harb, P. Volberding, and C. van der Horst NIAID, NIH AIDS Clin. Trials Group, Bethesda, MD
| ||
| 11:15 LB16. | A Clinical Trial Comparing Standard Treatment Modalities for Squamous Intraepithelial Lesions of the Cervix in HIV-Infected Women T. C. Wright*1, T. J. Bush2, D. Sawo1, L. J. Conley2, F. Wu1, and T. V. Ellerbrock2 1Columbia Univ., New York, NY and 2CDC, Atlanta, GA
| ||
| 11:30 LB17. | Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial E. Martinez1, D. Podzamczer2, E. Ribera3, P. Domingo4, H. Knobel5, D. Dalmau6, M. Riera7, E. Pedrol8, L. Force9, J. Llibre10, F. Segura11, C. Richart12, C. Cortes13, M. Javaloyas14, M. Aranda15, and J. M. Gatell1 1Hosp. Clinic, Barcelona, Spain; 2Hosp. Bellvitge, L'Hospitalet, Spain; 3Hosp. Vall d'Hebron, Barcelona, Spain; 4Hosp. Sant Pau, Barcelona, Spain; 5Hosp. del Mar, Barcelona, Spain; 6Mutua de Terrassa, Terrassa, Spain; 7Hosp. Son Dureta, Palma de Mallorca, Spain; 8Hosp. de Granollers, Granollers, Spain; 9Hosp. de Mataro, Mataro, Spain; 10Hosp. de Calella, Calella, Spain; 11CH Parc Tauli, Sabadell, Spain; 12Hosp. Joan XXIII, Tarragona, Spain; 13Hosp. Creu Roja, L'Hospitalet, Spain; 14Hosp. de Viladecans, Viladecans, Spain; and 15Hosp. de Terrassa, Terrassa, Spain
|
